{"DataElement":{"publicId":"4787972","version":"1","preferredName":"Minimal Residual Disease (MRD) End Consolidation Therapy Bone Marrow Sensitivity Value","preferredDefinition":"Sensitivity of Minimum residual disease status by flow cytometry, in bone marrow, end consolidation","longName":"4787956v1.0:4787953v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"4787956","version":"1","preferredName":"Minimal Residual Disease End Consolidation Therapy Bone Marrow Sensitivity","preferredDefinition":"remainder of a tumor or a neoplasm/cancer after primary, potentially curative therapy._The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours._A number with no fractional part.::43_Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains._A condition or state at a particular time._The point or place at which something terminates in time, space, or extent._Treatment that is given after cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. It may include radiation therapy, a stem cell transplant, or treatment with drugs that kill cancer cells._The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes._The ability to respond to physical stimuli or to register small physical amounts or differences.","longName":"2452232v1.0:4787954v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2452232","version":"1","preferredName":"Minimal Residual Disease","preferredDefinition":"remainder of a tumor or a neoplasm/cancer after primary, potentially curative therapy.","longName":"C3896","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Measurable Residual Disease","conceptCode":"C3896","definition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D052842-7AD9-4FD3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-22","modifiedBy":"ONEDATA","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4787954","version":"1","preferredName":"End Consolidation Therapy Bone Marrow Sensitivity","preferredDefinition":"The point or place at which something terminates in time, space, or extent.:Treatment that is given after cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. It may include radiation therapy, a stem cell transplant, or treatment with drugs that kill cancer cells.:The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.:The ability to respond to physical stimuli or to register small physical amounts or differences.","longName":"C25496:C15679:C12431:C25201","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"End","conceptCode":"C25496","definition":"The point or place at which something terminates in time, space, or extent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Consolidation Therapy","conceptCode":"C15679","definition":"Treatment that is given after initial therapy to kill any remaining cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Bone Marrow","conceptCode":"C12431","definition":"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Sensitivity","conceptCode":"C25201","definition":"The ability to respond to physical stimuli or to register small physical amounts or differences.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"135EEC98-D7AE-84BF-E050-BB89AD436F63","latestVersionIndicator":"Yes","beginDate":"2015-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-04-10","modifiedBy":"ONEDATA","dateModified":"2015-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"135EEC98-D7BF-84BF-E050-BB89AD436F63","latestVersionIndicator":"Yes","beginDate":"2015-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-04-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for TARGET harmonization project per request by T.Davidsen. mc 4/10/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4787953","version":"1","preferredName":"MRD Sensitivity Percent Value","preferredDefinition":"Numerical representation of the sensitivity of the minimum residual disease during induction therapy.","longName":"4787953v1.0","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","unitOfMeasure":"%","minLength":null,"maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":"2","PermissibleValues":[],"ConceptualDomain":{"publicId":"2842596","version":"1","preferredName":"Outcome of Therapy","preferredDefinition":"The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C18919 ","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63D982FA-DFBF-58C7-E040-BB89AD433E84","latestVersionIndicator":"Yes","beginDate":"2009-02-26","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-02-26","modifiedBy":"CURTIST","dateModified":"2009-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2414933","version":"1","preferredName":"Value","preferredDefinition":"A numerical quantity measured or assigned or computed.","longName":"C25712","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"02772734-9BE5-6ADF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-10-06","modifiedBy":"ONEDATA","dateModified":"2005-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"135EEC98-D785-84BF-E050-BB89AD436F63","latestVersionIndicator":"Yes","beginDate":"2015-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-04-10","modifiedBy":"COOPERM","dateModified":"2015-04-28","changeDescription":"Created for TARGET CDE harmonization project. mc 4/10/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5650570","version":"1","longName":"TARGET","context":"OCG","ClassificationSchemeItems":[{"publicId":"5650571","version":"1","longName":"ALL","context":"OCG"}]}],"AlternateNames":[{"name":"OCG","type":"USED_BY","context":"OCG"}],"ReferenceDocuments":[{"name":"Sensitivity of Minimum residu","type":"Preferred Question Text","description":"Sensitivity of Minimum residual disease status by flow cytometry, end consolidation of induction therapy","url":null,"context":"NCIP"},{"name":"Original TARGET Question Text","type":"Alternate Question Text","description":"Sensitivity of Minimum residual disease status, end consolidation of induction therapy","url":null,"context":"NCIP"},{"name":"Typical Dara Entry","type":"NOTE","description":"Typical entry will be 0.01% (default) or 0.1%","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"135EEC98-D995-84BF-E050-BB89AD436F63","latestVersionIndicator":"Yes","beginDate":"2015-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-04-10","modifiedBy":"COOPERM","dateModified":"2017-02-02","changeDescription":"Created for TARGET harmonization project per request by T.Davidsen. mc 4/10/2015 Updated definition and question text per request by Tanja. mc 12/22/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}